Septerna (NASDAQ:SEPN) Reaches New 12-Month High – Here’s Why

Septerna, Inc. (NASDAQ:SEPN) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $32.92 and last traded at $32.72, with a volume of 56398 shares traded. The stock had previously closed at $30.47.

Wall Street Analysts Forecast Growth

SEPN has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Stifel Nicolaus initiated coverage on Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price for the company. Raymond James Financial upped their target price on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a report on Monday. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Guggenheim initiated coverage on Septerna in a report on Thursday. They issued a “buy” rating and a $52.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.78.

Septerna Trading Up 6.9%

The firm has a market capitalization of $1.47 billion, a PE ratio of -40.30 and a beta of 2.39. The business has a fifty day moving average price of $26.55 and a two-hundred day moving average price of $26.67.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. On average, equities analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 21,733 shares of company stock valued at $623,707. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Hedge funds have recently bought and sold shares of the company. Group One Trading LLC lifted its stake in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the 4th quarter worth about $35,000. Russell Investments Group Ltd. acquired a new position in Septerna during the 3rd quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna during the 4th quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Septerna during the 4th quarter worth about $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.